FDA reverses course, will assessment Moderna’s new mRNA flu vaccine

Two weeks in the past, the FDA took the uncommon step of refusing to simply accept Moderna’s software for its first mRNA flu vaccine. After assembly with the corporate, the company has now agreed to assessment it.